This promotional message is being sent to you on behalf of Aerie Pharmaceuticals, Inc.
Can’t see this? |  View it online
M.O.S.T.: A Multi-center Open-label Study
A real-world experience trial
Additional >4 mmHg IOP reduction whether added to a PGA monotherapy or combination therapy1
Consistent IOP Reduction for more patients1,2
Rhopressa® provides consistent, additional IOP reduction regardless of the patient’s current regimen.1
Study design: Rhopressa® Multi-center Open-label Study (M.O.S.T.)
M.O.S.T. (12-week), prospective, multi-center, non-comparative, open-label study of 260 subjects diagnosed with OAG or OHT.
Primary Endpoint:
Percent change from baseline (BL) in mean IOP at Week 12
Secondary Endpoint:
Change from BL in mean IOP at Week 12
Mean IOP at Week 12
The most common ocular adverse event (AE) reported when Rhopressa® was used adjunctively was conjunctival hyperemia (19.9%), resulting in a discontinuation rate of 4.3%. Other common AEs were: blurred vision (6.2%), conjunctival hemorrhage (5.0%), and instillation site pain (5.0%).1
Bacterial Keratitis: There have been reports of bacterial keratitis associated with the use of multiple-dose containers of topical ophthalmic products. These containers had been inadvertently contaminated by patients who, in most cases, had a concurrent corneal disease or a disruption of the ocular epithelial surface.
Contact Lenses: Contact lenses should be removed prior to instillation of Rhopressa® and may be inserted 15 minutes following its administration.
The most common ocular adverse reaction observed in controlled clinical studies with Rhopressa® dosed once daily was conjunctival hyperemia, reported in 53% of patients. Six percent of patients discontinued therapy due to conjunctival hyperemia. Other common (approximately 20%) adverse reactions were: corneal verticillata, instillation site pain, and conjunctival hemorrhage. Instillation site erythema, corneal staining, blurred vision, increased lacrimation, erythema of eyelid, and reduced visual acuity were reported in 5-10% of patients.
The corneal verticillata seen in Rhopressa®- treated patients were first noted at 4 weeks of daily dosing. This reaction did not result in any apparent visual functional changes. Most corneal verticillata resolved upon discontinuation of treatment.
Please visit for full prescribing information for Rhopressa®.
You are encouraged to report negative side effects of prescription drugs to the FDA.
Rhopressa® (netarsudil ophthalmic solution) 0.02% is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
The recommended dosage is one drop in the affected eye(s) once daily in the evening.
Data on file, Aerie Pharmaceuticals, Inc.
Rhopressa® (netarsudil ophthalmic solution) 0.02% Prescribing Information, Aerie Pharmaceuticals, Inc., Irvine, Calif. 2019.
Khouri AS, Serle JB, Bacharach J, et al; for the ROCKET-4 Study Group. Once-daily netarsudil vs twice-daily timolol in patients with elevated intraocular pressure: the randomized phase 3 ROCKET-4 study. Am J Ophthalmol. 2019;204:97-104.
To unsubscribe from this program, click here.
Please do not reply to this email. This mailbox is not monitored.
©2020 Aerie Pharmaceuticals, Inc. All rights reserved.